6.85Open6.85Pre Close0 Volume0 Open Interest26.00Strike Price0.00Turnover0.00%IV-7.16%PremiumDec 20, 2024Expiry Date8.13Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.23Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
$Nxu Inc (NXU.US)$ grab some on your way out.
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
No comment yet